A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Status:
RECRUITING
Trial end date:
2032-06-01
Target enrollment:
Participant gender:
Summary
This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical (\[225Ac\]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to establish the maximum tolerated dose (MTD) or maximum administered dose (MAD) and the recommended Part 2 dose.